tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

PRNAF Stock Latest News

Alterity Therapeutics to Present at MST Financial Webinar
Press ReleasesAlterity Therapeutics to Present at MST Financial Webinar
4d ago
ATHE
Alterity Therapeutics Unveils Future in Investor Webinar
PremiumCompany Announcements
Alterity Therapeutics Unveils Future in Investor Webinar
4d ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
9d ago
ADVM
ALLO
Alterity Therapeutics Seeks ASX Quotation
PremiumCompany Announcements
Alterity Therapeutics Seeks ASX Quotation
9d ago
Alterity Therapeutics Plans New Share Issue
PremiumCompany Announcements
Alterity Therapeutics Plans New Share Issue
10d ago
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
PremiumPress ReleasesAlterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
11d ago
ATHE
Alterity Therapeutics reports interim data from ATH434-202 Phase 2 trial in MSA
PremiumThe Fly
Alterity Therapeutics reports interim data from ATH434-202 Phase 2 trial in MSA
11d ago
ATHE
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
PremiumPress Releases
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
11d ago
ATHE
Alterity’s ATH434 Shows Hope in MSA Trial
PremiumCompany Announcements
Alterity’s ATH434 Shows Hope in MSA Trial
11d ago
Alterity Therapeutics Halts Trading for Clinical Update
PremiumCompany Announcements
Alterity Therapeutics Halts Trading for Clinical Update
13d ago
Alterity Therapeutics Issues Millions of New Options
PremiumCompany Announcements
Alterity Therapeutics Issues Millions of New Options
30d ago
Alterity Therapeutics Showcases at Life Sciences Webinar
PremiumCompany Announcements
Alterity Therapeutics Showcases at Life Sciences Webinar
2M ago
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
PremiumPress ReleasesAlterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
2M ago
ATHE
Alterity Therapeutics Announces Option Cessation
PremiumCompany Announcements
Alterity Therapeutics Announces Option Cessation
2M ago
Alterity announces DMC recommends to continue Phase 2 study of ATH434-201
PremiumThe Fly
Alterity announces DMC recommends to continue Phase 2 study of ATH434-201
3M ago
ATHE
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
PremiumPress Releases
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
3M ago
ATHE
JPMorgan Chase Ends Major Stake in Alterity Therapeutics
PremiumCompany Announcements
JPMorgan Chase Ends Major Stake in Alterity Therapeutics
3M ago
BNYMC Ups Stake in Alterity Therapeutics
PremiumCompany Announcements
BNYMC Ups Stake in Alterity Therapeutics
3M ago
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
PremiumPress Releases
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
3M ago
ATHE
Alterity Therapeutics reports cash position of A$18.3M as of March 31
PremiumThe FlyAlterity Therapeutics reports cash position of A$18.3M as of March 31
3M ago
ATHE
Alterity Therapeutics presents new data demonstrating potential of ATH434
PremiumThe Fly
Alterity Therapeutics presents new data demonstrating potential of ATH434
3M ago
ATHE
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
PremiumPress Releases
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
3M ago
ATHE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >